Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=150 Randomized Triple-blind Treatment

Postoperative Pain Control Following Hysteroscopy

Postoperative Pain · Postoperative Nausea · Analgesia

Bottom Line

View on ClinicalTrials.gov: NCT06423456 ↗
Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Visual Analog Scale (VAS) — 2.49; 4.44; 1.23; 2.40 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lidocaine IV (Drug); Saline (Drug)
Age
Adult, Older Adult · 19+ yrs
Sex
Female
Sponsor
Afyonkarahisar Health Sciences University
Primary completion
Feb 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Scale (VAS)		 2.49; 4.44; 1.23; 2.40; 0.61; 1.09 —

Summary

Intraoperative lidocaine infusion is a frequently preferred method in surgical procedures due to its reducing the need for opioids, providing better postoperative pain control, reducing postoperative nausea and vomiting and increasing rapid recovery. Our aim in this study is to show the effect of intraoperative lidocaine infusion on reducing complications such as pain, nausea, vomiting, and the need for opioid analgesia that occur after hysteroscopy operations, which are often performed in gynecology clinics.

Eligibility Criteria

Inclusion Criteria

  • Female patients with ASA I-II according to the American Society of Anesthesiologists (ASA) classification who are scheduled for elective hysteroscopy with indications such as
  • abnormal uterine bleeding
  • endometrial polyp
  • submucosal myoma
  • foreign body in the endometrial cavity
  • infertility
  • intrauterine synechia

Exclusion Criteria

  • Patients under the age of 18
  • Who are allergic to lidocaine addicted to opioids or NSAIDs
  • Patients with chronic pain
  • Patients with severe systemic disease
  • Patients who do not approve
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06423456). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search